# SunRISe-1 (NCT04640623)

> A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04640623
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Urinary Bladder Neoplasms
- Interventions: TAR-200; Cetrelimab
- Enrollment: 220
- Primary outcome: Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate
- Primary outcome: Cohort 4: Disease-free Survival (DFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sunrise-1-nct04640623